Stockreport

Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials

Jupiter Neurosciences, Inc.  (JUNS) 
PDF Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company de [Read more]